BioNTech SE (NASDAQ:BNTX) and Matinas BioPharma Holdings Inc (NYSE:MTNB) have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas' proprietary LNC platform technology.
- The companies will collaborate on formulation, optimization, and in vitro testing.
- "We are thrilled to partner with this world-class organization to demonstrate the capabilities of our LNC platform further and potentially provide an opportunity for the oral administration of vaccines or other treatments,' said Jerome Jabbour, CEO & Co-Founder of Matinas.
- Related: Matinas BioPharma Stock Jumps After Meningitis Candidate Data.
- Under the agreement terms, Matinas will receive an upfront access fee to work exclusively with BioNTech and additional research funding from BioNTech. Specific deal terms were not disclosed.
- The parties have also commenced discussions on a license agreement for Matinas' LNC platform technology.
- Price Action: MTNB shares are up 2.97% at $0.80, and BNTX shares are down 0.70% at $169.06 on Monday's last check.
